Editorial
doi: 10.1200/JCO.2005.05.907.
Epub 2005 Jul 18.
Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development?
- PMID: 16027435
- DOI: 10.1200/JCO.2005.05.907
Item in Clipboard
Editorial
Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development?
J Clin Oncol.
.
No abstract available
Comment on
-
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.J Clin Oncol. 2005 Aug 20;23(24):5474-83. doi: 10.1200/JCO.2005.04.192. Epub 2005 Jul 18. J Clin Oncol. 2005. PMID: 16027439 Clinical Trial.
-
Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study.J Clin Oncol. 2005 Aug 20;23(24):5464-73. doi: 10.1200/JCO.2005.04.143. Epub 2005 Jul 18. J Clin Oncol. 2005. PMID: 16027440 Clinical Trial.
Similar articles
-
Inhibition of angiogenesis in cancer patients.Expert Opin Emerg Drugs. 2005 May;10(2):403-12. doi: 10.1517/14728214.10.2.403. Expert Opin Emerg Drugs. 2005. PMID: 15934875 Review.
-
The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials.Curr Mol Med. 2003 Dec;3(8):673-91. doi: 10.2174/1566524033479410. Curr Mol Med. 2003. PMID: 14682490 Review.
-
New drugs target hypoxia response in tumors.J Natl Cancer Inst. 2005 Aug 3;97(15):1112-4. doi: 10.1093/jnci/dji261. J Natl Cancer Inst. 2005. PMID: 16077066 No abstract available.
-
Targeting angiogenesis with oral agents.Ann Oncol. 2006 Sep;17 Suppl 10:x71-5. doi: 10.1093/annonc/mdl240. Ann Oncol. 2006. PMID: 17018755 Review. No abstract available.
-
Clinical biomarkers of angiogenesis inhibition.Cancer Metastasis Rev. 2008 Sep;27(3):415-34. doi: 10.1007/s10555-008-9143-x. Cancer Metastasis Rev. 2008. PMID: 18414993 Free PMC article. Review.
Cited by
-
Phase 0 clinical trials in oncology new drug development.Perspect Clin Res. 2011 Jan;2(1):13-22. doi: 10.4103/2229-3485.76285. Perspect Clin Res. 2011. PMID: 21584177 Free PMC article.
-
Drug development in oncology: classical cytotoxics and molecularly targeted agents.Br J Clin Pharmacol. 2006 Jul;62(1):15-26. doi: 10.1111/j.1365-2125.2006.02713.x. Br J Clin Pharmacol. 2006. PMID: 16842375 Free PMC article. Review.
-
Next generation oncology drug development: opportunities and challenges.Nat Rev Clin Oncol. 2009 May;6(5):259-65. doi: 10.1038/nrclinonc.2009.38. Nat Rev Clin Oncol. 2009. PMID: 19390552 Free PMC article. Review.
-
Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer.ISRN Cell Biol. 2012;2012:587259. doi: 10.5402/2012/587259. ISRN Cell Biol. 2012. PMID: 24340224 Free PMC article.
-
Imaging in drug development: will it deliver on the promise of personalised medicine?Br J Radiol. 2010 Jun;83(990):453-5. doi: 10.1259/bjr/65491666. Br J Radiol. 2010. PMID: 20505028 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
